Taysha Gene Therapies Stock Probability of Future Stock Price Finishing Under 3.47
| TSHA Stock | USD 2.40 0.12 4.76% |
Taysha |
Taysha Gene Target Price Odds to finish below 3.47
The tendency of Taysha Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 3.47 after 90 days |
| 2.40 | 90 days | 3.47 | close to 99 |
Based on a normal probability distribution, the odds of Taysha Gene to stay under $ 3.47 after 90 days from now is close to 99 (This Taysha Gene Therapies probability density function shows the probability of Taysha Stock to fall within a particular range of prices over 90 days) . Probability of Taysha Gene Therapies price to stay between its current price of $ 2.40 and $ 3.47 at the end of the 90-day period is about 23.04 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.67 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Taysha Gene will likely underperform. Additionally Taysha Gene Therapies has an alpha of 0.2261, implying that it can generate a 0.23 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Taysha Gene Price Density |
| Price |
Predictive Modules for Taysha Gene
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Taysha Gene Therapies. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Taysha Gene Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Taysha Gene is not an exception. The market had few large corrections towards the Taysha Gene's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Taysha Gene Therapies, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Taysha Gene within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.23 | |
β | Beta against Dow Jones | 1.67 | |
σ | Overall volatility | 0.38 | |
Ir | Information ratio | 0.04 |
Taysha Gene Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Taysha Gene for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Taysha Gene Therapies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Taysha Gene is way too risky over 90 days horizon | |
| Taysha Gene appears to be risky and price may revert if volatility continues | |
| Taysha Gene has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 15.45 M. Net Loss for the year was (111.57 M) with profit before overhead, payroll, taxes, and interest of 2.5 M. | |
| Taysha Gene Therapies currently holds about 66.24 M in cash with (73.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61. | |
| Taysha Gene has a frail financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Fmr LLC Has 37.54 Million Stake in Taysha Gene Therapies, Inc. - MarketBeat |
Taysha Gene Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Taysha Stock often depends not only on the future outlook of the current and potential Taysha Gene's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Taysha Gene's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 116.1 M | |
| Cash And Short Term Investments | 143.9 M |
Taysha Gene Technical Analysis
Taysha Gene's future price can be derived by breaking down and analyzing its technical indicators over time. Taysha Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Taysha Gene Therapies. In general, you should focus on analyzing Taysha Stock price patterns and their correlations with different microeconomic environments and drivers.
Taysha Gene Predictive Forecast Models
Taysha Gene's time-series forecasting models is one of many Taysha Gene's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Taysha Gene's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Taysha Gene Therapies
Checking the ongoing alerts about Taysha Gene for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Taysha Gene Therapies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Taysha Gene is way too risky over 90 days horizon | |
| Taysha Gene appears to be risky and price may revert if volatility continues | |
| Taysha Gene has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 15.45 M. Net Loss for the year was (111.57 M) with profit before overhead, payroll, taxes, and interest of 2.5 M. | |
| Taysha Gene Therapies currently holds about 66.24 M in cash with (73.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61. | |
| Taysha Gene has a frail financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Fmr LLC Has 37.54 Million Stake in Taysha Gene Therapies, Inc. - MarketBeat |
Check out Taysha Gene Backtesting, Taysha Gene Valuation, Taysha Gene Correlation, Taysha Gene Hype Analysis, Taysha Gene Volatility, Taysha Gene History as well as Taysha Gene Performance. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share 0.042 | Quarterly Revenue Growth (0.62) | Return On Assets (0.27) | Return On Equity (1.15) |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.